Burning Rock Biotech Limited's (NASDAQ:BNR) largest shareholders are individual investors with 29% ownership, institutions own 26%

Burning Rock Biotech Limited's (NASDAQ:BNR) largest shareholders are individual investors with 29% ownership, institutions own 26%

Trade BNR on Coinbase

Key Insights

  • The considerable ownership by individual investors in Burning Rock Biotech indicates that they collectively have a greater say in management and business strategy

  • A total of 5 investors have a majority stake in the company with 50% ownership

  • Insider ownership in Burning Rock Biotech is 18%

To get a sense of who is truly in control of Burning Rock Biotech Limited (NASDAQ:BNR), it is important to understand the ownership structure of the business. We can see that individual investors own the lion's share in the company with 29% ownership. Put another way, the group faces the maximum upside potential (or downside risk).

And institutions on the other hand have a 26% ownership in the company. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies.

In the chart below, we zoom in on the different ownership groups of Burning Rock Biotech.

Check out our latest analysis for Burning Rock Biotech

ownership-breakdown
NasdaqGM:BNR Ownership Breakdown October 31st 2023

What Does The Institutional Ownership Tell Us About Burning Rock Biotech?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

Burning Rock Biotech already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Burning Rock Biotech, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
NasdaqGM:BNR Earnings and Revenue Growth October 31st 2023

Hedge funds don't have many shares in Burning Rock Biotech. Looking at our data, we can see that the largest shareholder is the CEO Yusheng Han with 16% of shares outstanding. In comparison, the second and third largest shareholders hold about 11% and 8.1% of the stock.

On looking further, we found that 50% of the shares are owned by the top 5 shareholders. In other words, these shareholders have a meaningful say in the decisions of the company.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. While there is some analyst coverage, the company is probably not widely covered. So it could gain more attention, down the track.